Read by QxMD icon Read


Jose Abraão Carneiro Neto, Silvane Braga Santos, Gloria Orge Orge, Davi Tanajura, Lucia Passos, Cassius José Oliveira, Rosana Andrade, Cláudio Galeno de Melo, Ubirajara Barroso, Edgar M Carvalho
AIM: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on QoL. METHODS: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King's Health Questionnaire. RESULTS: The mean (SD) of the age was 52+14...
February 17, 2018: Brazilian Journal of Infectious Diseases
Priyesh N Patel, Edmond K Kabagambe, Jennifer C Starkweather, Matthew Keller, Vahram Gamsarian, Jane Lee, Vishnutheert Kulkarni, C Gaelyn Garrett, David O Francis
Importance: The relative outcomes of onabotulinum toxin A injections for treatment of adductor spasmodic dysphonia (ADSD), ADSD with lateral laryngeal tremor (ADSD+LT), and lateral LT without ADSD are unclear. Objective: To compare the outcomes of onabotulinum toxin A treatment on ADSD, ADSD+LT, and lateral LT without ADSD. Design, Setting, and Participants: A retrospective cohort study was conducted from January 1, 1990, to September 30, 2016, at a tertiary referral voice center...
February 8, 2018: JAMA Otolaryngology—Head & Neck Surgery
Joline E Brandenburg, Sarah F Eby, Pengfei Song, William Bamlet, Gary C Sieck, Kai-Nan An
OBJECTIVE: A pilot study to longitudinally quantify effect of onabotulinum toxin A (BoNT-A) on passive muscle properties in children with cerebral palsy (CP) using ultrasound shear wave elastography (SWE). DESIGN: Prospective longitudinal cohort study RESULTS: Between 1 and 3 months post-BoNT-A, a significant improvement in the shear modulus of the lateral gastrocnemius was found at 10° plantar flexion (PF) (-7.57 [-10.98, -5.07], p=0.02) and 0° PF (-14.74 [-18...
February 5, 2018: American Journal of Physical Medicine & Rehabilitation
Casey G Kowalik, Joshua A Cohn, Andrea Kakos, Patrick Lang, W Stuart Reynolds, Melissa R Kaufman, Mickey M Karram, Roger R Dmochowski
INTRODUCTION AND HYPOTHESIS: Urethral injury resulting from transvaginal mesh slings is a rare complication with an estimated incidence of <1%. Our objective was to review the surgical management and functional outcomes of women presenting with urethral mesh perforation following midurethral sling (MUS) placement. METHODS: This was a retrospective multicenter review of women who from January 2011 to March 2016 at two institutions underwent mesh sling excision for urethral perforation with Female Pelvic Medicine and Reconstructive Surgery fellowship-trained surgeons...
January 29, 2018: International Urogynecology Journal
William G Ondo, Jerald H Simmons, Muhammad H Shahid, Vera Hashem, Christine Hunter, Joseph Jankovic
OBJECTIVES: To test the safety and efficacy of onabotulinum toxin-A (BoNT-A) injections into the masseter and temporalis muscles in patients with symptomatic sleep bruxism. METHODS: Participants 18 to 85 years old with clinically diagnosed sleep bruxism confirmed by polysomnography were enrolled in this randomized, placebo-controlled, 1:1, parallel-design trial with open-label extension. Participants were injected with BoNT-A 200 units (60 into each masseter and 40 into each temporalis) or placebo and were evaluated at 4 to 8 weeks after the initial treatment visit...
February 13, 2018: Neurology
Todd A Linsenmeyer
This review is based on the author's Donald Munro Lecture given at the annual conference of the Academy of Spinal Cord Injury Professionals in New Orleans, LA. Indwelling catheters play an important role in bladder management following SCI for many individuals with neurogenic bladders. There is an increased risk of UTI compared to other types of bladder management with indwelling urethral catheters but not SP catheters. To minimize the risk of symptomatic UTI, the following steps are essential: prevent bladder wall distention and resulting ischemia, maintain colonization with "good" bacteria, and prevent bladder stones...
March 2018: Journal of Spinal Cord Medicine
Helka M Heikkilä, Tarja S Jokinen, Pernilla Syrjä, Jouni Junnila, Anna Hielm-Björkman, Outi Laitinen-Vapaavuori
OBJECTIVE: To investigate the clinical, cytological, and histopathological adverse effects of intra-articularly injected botulinum toxin A in dogs and to study whether the toxin spreads from the joint after the injection. METHODS: A longitudinal, placebo-controlled, randomized clinical trial was conducted with six healthy laboratory Beagle dogs. Stifle joints were randomized to receive either 30 IU of onabotulinum toxin A or placebo in a 1:1 ratio. Adverse effects and spread of the toxin were examined by evaluating dynamic and static weight-bearing of the injected limbs, by assessing painless range of motion and pain on palpation of joints, and by performing synovial fluid analysis, neurological examination, and electrophysiological recordings at different examination time-points in a 12-week period after the injections...
2018: PloS One
R J A van Moorselaar, Jakko A Nieuwenhuijzen
A woman experiencing very strong urgency and associated frequency of micturition, but no incontinence, and deep dyspareunia was eventually diagnosed with idiopathic detrusor overactivity with symptoms of overactive bladder symptom complex and potentially bladder pain syndrome. A trial of neuromodulation was unsuccessful, but injections of onabotulinum toxin A have had a good effect.
December 20, 2017: European Urology Focus
Néha Sihra, Jeremy Ockrim, Dan Wood
OBJECTIVES: To identify the rate of postoperative complications in patients who require surgical reconstruction for ketamine-induced urinary tract dysfunction and to identify any predictors for poor postoperative outcome with subsequent management strategies. PATIENTS AND METHODS: A retrospective review of data collected between 2007 and 2017 of all patients with ketamine-induced urinary tract disease was performed. Evaluation included computed tomography urogram, cystoscopy, and biopsy...
March 2018: BJU International
Tommy L H Chan, Werner J Becker, William Y Hu, Farnaz Amoozegar
No abstract text is available yet for this article.
November 6, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
María Luz Cuadrado, Pedro López-Ruiz, Ángel L Guerrero
Nummular headache (NH) is characterized by continuous or intermittent head pain, which remains confined to a round or oval shaped area of the scalp, generally 1 to 6 cm in diameter. Usually mild or moderate in intensity, some patients suffer severe acute exacerbations or continuous disabling pain. Areas covered: This article reviews epidemiological and clinical features of NH, the most recently proposed pathophysiological mechanisms, and state-of-the-art management according to the literature. Expert commentary: Information regarding true incidence and prevalence is lacking, but NH is a fairly common disorder in patients attending a headache clinic...
January 2018: Expert Review of Neurotherapeutics
Piero Barbanti, Patrizia Ferroni
Discovered by serendipity, onabotulinum toxin A (BoNT-A) is the only US Food and Drug Administration-approved treatment for the prevention of chronic migraine (CM), one of the most disabling and burdensome human conditions. Its efficacy, safety and tolerability, proved by the largest and longest migraine therapeutic trial (the Phase III Research Evaluating Migraine Prophylaxis Therapy program [PREEMPT]), have been replicated by various real-life studies also in the presence of medication overuse. The benefit of BoNT-A prophylaxis is likely due to its ability to counteract peripheral and central nociceptive sensitization through reversible chemical denervation of pericranial sensitive afferents...
2017: Journal of Pain Research
R Pinto, D Costa, A Morgado, P Pereira, A Charrua, J Silva, F Cruz
PURPOSE: To compare efficacy and safety of trigonal injections of onabotulinumtoxinA and saline in Bladder Pain Syndrome/Interstitial Cystitis patients. MATERIALS AND METHODS: This phase II study enrolled women with Bladder Pain Syndrome/Interstitial Cystitis >6months and pain ≥4 in 0-10 visual analogue scale, refractory to common treatment. OnabotulinumtoxinA 100U (n=10) or saline (placebo, n=9), were administered as 10 trigonal injections of 1ml. Primary end-point was change from baseline in pain intensity reported at week 12...
October 12, 2017: Journal of Urology
Shannon Humphrey
<p>Onabotulinum Toxin A is the gold standard treatment for temporary dynamic rhytid reduction. Clinicians have observed a long-term and preventive benefit for patients beyond muscle relaxation particularly in patients who receive repeated treatments over time. These changes include progressive reduction of rhytides, prevention of dynamic rhytides, and improvements in skin quality. In this brief paper, we review basic science, clinical, and anecdotal evidence that explores a long-term and potential preventive effect of Onabotulinum Toxin A injections...
June 1, 2017: Journal of Drugs in Dermatology: JDD
Cagri Akin Sekerci, Yiloren Tanidir, Asgar Garayev, Cem Akbal, Tufan Tarcan, Ferruh Simsek
OBJECTIVE: To determine the efficacy and safety of repeated intradetrusor onabotulinum toxin A (onaBoNT-A) injections in children with neurogenic detrusor overactivity due to myelodysplasia. METHODS: The study group consisted of 19 children (4 boys, 15 girls), with a mean age of 10.3±3.1 years old, who had received at least two injections of 10 U/kg onaBoNT-A for the treatment of urinary incontinence resistant to anticholinergic treatment and clean intermittent catheterization in our clinic, between 2010 and 2015...
September 21, 2017: Urology
José Javier Fabuel Alcañiz, Laura Martínez Arcos, Miguel Jimenez Cidre, Francisco Javier Burgos Revilla
Bladder hyperactivity is described as the presence of "voiding urgency, generally associated with increased daytime frequency and nocturia, with or without urinary incontinence, in the absence of urinary tract infection or other obvious pathology". Onabotulinum toxin A (BTA) is a recommendable therapeutic option in case of failure, contraindication or refusal of the conservative therapy or other non-pharmacological therapies. The injection of BTA in the detrusor has been performed under local, regional or general anesthesia either in the conventional or major ambulatory surgery operative room or in the cystoscopy room...
September 2017: Archivos Españoles de Urología
David A Hart, Rafael Fortuna, Walter Herzog
INTRODUCTION: Onabotulinum toxin-A (BoNT-A) is widely used clinically, but might cause adverse effects. Earlier studies showed repeat BoNT-A injections did not cause progressive atrophy or function loss. The purpose of this study was to assess the influence of repeat BoNT-A injections into rabbit muscle on subsequent molecular alterations. METHODS: Twenty-two rabbits received 0, 1, 2, or 3 BoNT-A injections in the quadriceps femoris muscle at 3 month intervals and were sacrificed 6 months after the last injection...
August 18, 2017: Muscle & Nerve
Hyun Jung Chang, Bo Young Hong, Sang-Jee Lee, Soyoung Lee, Joo Hyun Park, Jeong-Yi Kwon
The objective of this clinical trial was to compare the efficacy and safety of letibotulinum toxin A and onabotulinum toxin A for improving dynamic equinus foot deformity in children with cerebral palsy (CP). In total, 144 children with spastic CP who had dynamic equinus foot deformity were assigned randomly to the Botulax group (injection of letibotulinum toxin A) or the Botox group (injection of onabotulinum toxin A). The Physician's Rating Scale (PRS), ankle plantar flexor spasticity using the Modified Tardieu Scale, the Gross Motor Function Measure (GMFM)-88, and the GMFM-66 were completed before injection and at 6, 12, and 24 weeks after injection...
August 18, 2017: Toxins
Michał Szczypior, Wojciech Połom, Marcin Markuszewski, Krzesimir Ciura, Magdalena Buszewska-Forajta, Julia Jacyna, Michał Markuszewski, Marcin Matuszewski
OBJECTIVE: The aim of this study was to test the addition of methylene blue (MB) to onabotulinum toxin A (BTX-A) solution in overactive bladder (OAB) treatment, as a means of facilitating observation of the injection site and assessing the distribution of the drug under the bladder mucosa during injection. Pharmacological interactions between BTX-A and MB were also evaluated. MATERIALS AND METHODS: The study was conducted between December 2014 and April 2016 on 30 patients: six males and 24 females (median age 57...
December 2017: Scandinavian Journal of Urology
Gerard E Francisco, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi
OBJECTIVE: The main aim of this study was to determine the utilization patterns and effectiveness of onabotulinumtoxinA (Botox®) for treatment of spasticity in clinical practice. DESIGN: An international, multicentre, prospective, observational study at selected sites in North America, Europe, and Asia. PATIENTS: Adult patients with newly diagnosed or established focal spasticity, including those who had previously received treatment with onabotulinum-toxin A...
August 31, 2017: Journal of Rehabilitation Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"